Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Mesoblast Limited — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.15 (market cap $17.89B), while Mesoblast Limited trades at $14.33 (market cap $1.75B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 10.2× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 44,866,592). Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days and Mesoblast Limited for 14 Days on average.
| HYG | MESO | |
|---|---|---|
Market Cap | $17.89B | $1.75B |
Volume | 44,866,592 | 239,027 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $20.96 |
52-Week Low | $76.90 | $13.19 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.18, down 0.12% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces pressure from rising Treasury yields impacting high-yield bond valuations. Recent dividend payments of $0.34-$0.44 provide income support amid market volatility.
The outlook remains challenged by persistent bond market selloffs and higher interest rates, though the current yield environment may attract income-seeking investors. Key risks include further Fed tightening and economic slowdown impacting corporate credit quality.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
